Ana Claudia Cavalcante Nogueira, Joaquim Barreto, Filipe A Moura, Beatriz Luchiari, Abrão Abuhab, Isabella Bonilha, Wilson Nadruz, J Michael Gaziano, Thomas Gaziano, Luiz Sergio F de Carvalho, Andrei C Sposito
BACKGROUND: The escalating prevalence of type 2 diabetes (T2DM) poses an unparalleled economic catastrophe to developing countries. Cardiovascular diseases remain the primary source of costs among individuals with T2DM, incurring expenses for medications, hospitalizations, and surgical interventions. Compelling evidence suggests that the risk of cardiovascular outcomes can be reduced by three classes of glucose-lowering therapies (GLT), including SGLT2i, GLP-1A, and pioglitazone. However, an evidence-based and cost-effective protocol is still unavailable for many countries...
October 25, 2023: Health Economics Review